Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 1:19 PM
Ignite Modification Date:
2025-12-26 @ 1:19 PM
NCT ID:
NCT04436406
Eligibility Criteria:
Inclusion Criteria:
* Aged 18 or above
* Patients with histologically confirmed NSCLC or melanoma scheduled for PD1/PDL1 immunotherapy alone or in combination with other systemic anti-cancer therapy.
* Willingness and ability to comply with scheduled study visits and tests.
Exclusion Criteria:
* Pregnant or lactating women
* Concomitant uncontrolled medical conditions
* Patients likely to require palliative radiotherapy within the first 12 weeks of treatment or radiotherapy to target lesion(s) received within preceding 42 days
* More than 3 months between IHC PDL1 and study recruitment
* Patients who have received other systemic anti-cancer therapy within preceding 14 days
* Prognosis less than 3 months
* Previous anticancer treatment with any checkpoint inhibitor or other immunotherapy, i.e. only immunotherapy naïve patients
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04436406
Study Brief:
Protocol Section:
NCT04436406